SEC For	m 4																	
	FORM	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				Filed p	ursuant	t to Section	n 16(ES IN B a) of the Sec	curities	s Exchan	_	OMB Numbe Estimated av hours per res			ge burden	235-0287 0.5		
1. Name and Address of Reporting Person [*] Matsuda Kazuko					2. Issuer Name and Ticker or Trading Symbol <u>MEDICINOVA INC</u> [MNOV]								elationship o eck all applica X Director	able)	10% Owner			
(Last) (First) (Middle) C/O MEDICINOVA, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/02/2021								X Officer (give title Other (specify below) below) Chief Medical Officer				pecify	
4275 EX (Street) LA JOLI	ECUTIVE	TE 300 92037	4	. If Ame	endment, I	Date (of Original Filed (Month/Day/Year)				Line) X Form fil	int/Group Filing (Check Applicab ed by One Reporting Person ed by More than One Reporting					
(City) (State) (Zip)													Person					
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans: Date (Month/L)				ransacti e	ction 2A. Deemed Execution Date		3. Transaction Code (Instr		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		ed (A) or	5. Amoun	s ly pllowing	6. Owner Form: Di (D) or Inc (I) (Instr.	rect Ir lirect B 4) O	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount (A) or (D)		Price	Transacti (Instr. 3 a	on(s)			nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Day	Date		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	y Di or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		piration ite	Title	Amount or Number of Shares		(Instr. 4)				
Employee Stock Option (Right to Buy)	\$6.89	02/02/2021		A		325,000		02/02/2021	01/	/08/2030	Common Stock	325,000	\$0	325,000 ⁽	1)	D		

Explanation of Responses:

1. On January 9, 2020, the reporting person was granted an option to purchase 325,000 shares of common stock. The option vests based on the satisfaction of certain performance criteria for the fiscal year ended December 31, 2020. Such performance criteria for 2020 have been met, resulting in full vesting of the option.

<u>/s/ Yuichi Iwaki, attorney-in-</u>	02/04/2021				
<u>fact</u>	02/04/2021				

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.